Huntingtin‐lowering strategies in Huntington's disease: Antisense oligonucleotides, small RNAs, and gene editing
The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
The idea to lower mutant huntingtin is especially appealing in Huntington's disease (HD). It is autosomal dominant, so that expression of the mutant allele causes the disease. Advances in RNA and gene regulation provide foundations for the huntingtin gene (both normal and mutant alleles) and possibly the mutant allele only. There is much preclinical animal work to support the concept of gene and RNA silencing, but, to date, no clinical studies have been attempted in HD. Preventing expression of mutant huntingtin protein is at the cusp for a human trial. Antisense oligonucleotides delivered to patients with amyotrophic lateral sclerosis have been well tolerated; small RNAs administered to rodent and nonhuman primate brain knocked down huntingtin messenger RNA (mRNA); short‐hairpin complementary DNA of microRNAs can be expressed in adeno‐associated virus to provide long‐term silencing of huntingtin mRNA and protein. We expect that these approaches will be ready for clinical studies in the near future, once safety has been validated. Our understanding of gene editing—changing the huntingtin gene itself—is rapidly progressing. Harnessing our knowledge of transcription and translation should push scientific creativity to new and exciting advances that overcome the lethality of the mutant gene in HD. © 2014 International Parkinson and Movement Disorder Society
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Repurposing CRISPR as an RNA-Guided Platform for Sequence-Specific Control of Gene Expression
Qi, L. S., Larson, M. H., Gilbert, L. A., Doudna, J. A., Weissman, J. S., Arkin, A. P., & Lim, W. A. (2013) · Cell · doi:10.1016/j.cell.2013.02.022 · Cited by 5,016
Expression profiling reveals off-target gene regulation by RNAi
Jackson, A. L., Bartz, S. R., Schelter, J., Kobayashi, S. V., Burchard, J., Mao, M., Li, B., Cavet, G., & Linsley, P. S. (2003) · Nature Biotechnology · doi:10.1038/nbt831 · Cited by 2,370 · cited 1×
“siRNAs have good, but imperfect, fidelity; other mRNA targets might be affected.(14,15) siRNAs require a small sequence with complementarity to detect the mRNA target (seed sequence), but they can have single-nucleotide discrimination.”
BackgroundFatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways
Grimm, D., Streetz, K. L., Jopling, C. L., Storm, T. A., Pandey, K., Davis, C. R., Marion, P., Salazar, F., & Kay, M. A. (2006) · Nature · doi:10.1038/nature04791 · Cited by 1,677 · cited 1×
“Loss of exportin-5 function may be toxic.(27) Safety of AAV-delivered miRNA depends on the extent of miRNA expression and selectivity in targeting.”
BackgroundTALENs: A widely applicable technology for targeted genome editing
Joung, J. K., & Sander, J. D. (2013) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3486 · Cited by 1,650
Cas9 as a versatile tool for engineering biology
Mali, P., Esvelt, K. M., & Church, G. M. (2013) · Nature Methods · doi:10.1038/nmeth.2649 · Cited by 1,197
Kordasiewicz, H. B., Stanek, L. M., Wancewicz, E. V., Mazur, C., McAlonis, M. M., Pytel, K. A., Artates, J. W., Weiss, A., Cheng, S. H., Shihabuddin, L. S., et al. (2012) · Neuron · doi:10.1016/j.neuron.2012.05.009 · Cited by 770 · cited 3×
“(without detailed histology) for at least a few months.(12) ASOs use RNase H to cleave huntingtin mRNA.”
BackgroundInfluentialHarper, S. Q., Staber, P. D., He, X., Eliason, S. L., Martins, I. H., Mao, Q., Yang, L., Kotin, R. M., Paulson, H. L., & Davidson, B. L. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501507102 · Cited by 682
Miller, T. M., Pestronk, A., David, W., Rothstein, J., Simpson, E., Appel, S. H., Andres, P. L., Mahoney, K., Allred, P., Alexander, K., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70061-9 · Cited by 617 · cited 2×
“The mutation is an increase in a series of CAG repeats near the start site of the huntingtin gene.(1) There are a few gaps in the genetic principle.”
BackgroundDavidson, B. L., Stein, C. S., Heth, J. A., Martins, I., Kotin, R. M., Derksen, T. A., Zabner, J., Ghodsi, A., & Chiorini, J. A. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.7.3428 · Cited by 531
Safety and tolerability of putaminal AADC gene therapy for Parkinson disease
Christine, C. W., Starr, P. A., Larson, P. S., Eberling, J. L., Jagust, W. J., Hawkins, R. A., VanBrocklin, H. F., Wright, J. F., Bankiewicz, K. S., & Aminoff, M. J. (2009) · Neurology · doi:10.1212/wnl.0b013e3181c29356 · Cited by 445 · cited 1×
“AAV continues to deliver its cargo for many years in nonhuman primates and humans.(32) The goal of the therapy would be that single administration of AAV with a short-hairpin–containing microRNA (shRNAmir) into the striatum and areas of the cortex silences mutant huntingtin for many years.”
BackgroundZhang, H., Yang, B., Mu, X., Ahmed, S. S., Su, Q., He, R., Wang, H., Mueller, C., Sena-Esteves, M., Brown, R., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2011.98 · Cited by 291 · cited 1×
“AAV is generally delivered by direct brain injection, because, in the current technology, few neurons will take up AAV from the circulation.(28,29) AAV administration is best achieved in the brain by convection enhanced delivery, under constant pressure.”
BackgroundPfister, E. L., Kennington, L., Straubhaar, J., Wagh, S., Liu, W., DiFiglia, M., Landwehrmeyer, B., Vonsattel, J.-P., Zamore, P. D., & Aronin, N. (2009) · Current Biology · doi:10.1016/j.cub.2009.03.030 · Cited by 261 · cited 11×
“Harnessing our knowledge of transcription and translation should push scientific creativity to new and exciting advances that overcome the lethality of the mutant gene in HD. VC 2014 International Parkinson and Movement Disorder Society Key Words: Huntington’s disease; huntingtin; gene regulation; clinical trial”
BackgroundInfluentialSelf-citationRegulation of Postsynaptic Retrograde Signaling by Presynaptic Exosome Release
Korkut, C., Li, Y., Koles, K., Brewer, C., Ashley, J., Yoshihara, M., & Budnik, V. (2013) · Neuron · doi:10.1016/j.neuron.2013.01.013 · Cited by 250
McBride, J. L., Pitzer, M. R., Boudreau, R. L., Dufour, B., Hobbs, T., Ojeda, S. R., & Davidson, B. L. (2011) · Molecular Therapy · doi:10.1038/mt.2011.219 · Cited by 247 · cited 1×
“AAV-shRNAmir has been used to ameliorate neurodegeneration of mutant huntingtin in mice,(26,33,34) and short-term studies of safety in nonhuman primates look promising.(35,36) An improvement in AAV-based therapy would be regulation of AAV-shRNAmir production in vivo, so that miRNA production can be curtailed or shut o…”
MethodHadaczek, P., Forsayeth, J., Mirek, H., Munson, K., Bringas, J., Pivirotto, P., L McBride, J., Davidson, B. L., & Bankiewicz, K. S. (2009) · Human Gene Therapy · doi:10.1089/hum.2008.151 · Cited by 90
Cited by
Genome-editing Technologies for Gene and Cell Therapy
Maeder, M. L., & Gersbach, C. A. (2016) · Molecular Therapy · doi:10.1038/mt.2016.10 · Cited by 719
Identification of Genetic Factors that Modify Clinical Onset of Huntington’s Disease
Lee, J.-M., Wheeler, V. C., Chao, M. J., Vonsattel, J. P. G., Pinto, R. M., Lucente, D., Abu-Elneel, K., Ramos, E. M., Mysore, J. S., Gillis, T., et al. (2015) · Cell · doi:10.1016/j.cell.2015.07.003 · Cited by 655
“Because targets validated to impact on the disease process in humans have been lacking for traditional small-molecule approaches to drug development, a current focus for developing an effective disease-modifying therapy is the exploration of cutting-edge nucleic acid manipulation to prevent expression of mutant huntin…”
Wang, G., Liu, X., Gaertig, M. A., Li, S., & Li, X.-J. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1524575113 · Cited by 146
“…of HD animal models that express mutant HTT provide strong evidence for an age-dependent toxic gain of function of mutant HTT (8 – 12), and considerable efforts have been devoted to developing siRNA and antisense oligonucleotides to suppress the expression of mutant HTT in adult brains (13 – 15).”
BackgroundHuntingtin suppression restores cognitive function in a mouse model of Huntington’s disease
Southwell, A. L., Kordasiewicz, H. B., Langbehn, D., Skotte, N. H., Parsons, M. P., Villanueva, E. B., Caron, N. S., Østergaard, M. E., Anderson, L. M., Xie, Y., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aar3959 · Cited by 126
Destination Brain: the Past, Present, and Future of Therapeutic Gene Delivery
Joshi, C. R., Labhasetwar, V., & Ghorpade, A. (2017) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-016-9724-3 · Cited by 55
“The number of CAG repeats is linked to disease severity, thus, gene editing methods that precisely remove excessive CAG repeats may attenuate disease pathology (Aronin and DiFiglia 2014).”
Metadata
- Authors
- Aronin, N., & DiFiglia, M.
- Venue
- Movement Disorders
- Publisher
- Wiley
- Published
- 2014-08-27
- Volume
- 29
- Issue
- 11
- Pages
- 1455-1461
- ISSN
- 0885-3185 (ISSN-L)
- 1531-8257
- OpenAlex
- W1628568478
- Cited by
- 81
- References
- 15
- FWCI
- 3.62
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.